Dr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form 20-F
Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced that its Annual Report in Form 20-F, containing its annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS), as issued by International Accounting Standards Board (IASB), for the fiscal year ended March 31, 2026 was filed with the United States Securities and Exchange Commission on May 29, 2026.
The Annual Report on Form 20-F is also available on Dr. Reddy’s website, www.drreddys.com and can be accessed at https://www.drreddys.com/cms/sites/default/files/2026-05/Form_20F_March_2026.pdf. American Depositary Receipts (ADRs) holders may also obtain a hard copy of the Annual Report in Form 20-F at no cost by sending a written request to the Company’s registered office address or by sending an e-mail to shares@drreddys.com.
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait,’ we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance.
